Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1029

Registration Number: NCT02248142

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Tipranavir (TPV)
Drug: Ritonavir (r)

First Posted Date: 2014-09-25

Last Posted Date: 2025-01-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02249442

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir (TPV)
Drug: Ritonavir (RTV)
Drug: Delavirdine (DLV)
Drug: Zidovudine (ZDV)
Drug: Lamivudine (3TC)
Drug: Stavudine (d4T)

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02249130

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1449

Registration Number: NCT02248168

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BIIL 284 BS
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT02249338

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Talsaclidine 36 mg
Drug: Talsaclidine 12 mg
Drug: Talsaclidine 6 mg
Drug: Talsaclidine 24 mg
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 362

Registration Number: NCT02249403

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Phase 1

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: High dose of BIIL 284 BS tablets
Drug: Low dose of BIIL 284 BS tablets
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02247375

Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir (TPV) low
Drug: Tipranavir (TPV) high
Drug: Ritonavir (RTV) low
Drug: Ritonavir (RTV) high
Drug: Zidovudine

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02249416

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: BIIL 284 BS
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38

Registration Number: NCT02249312

Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1293

Registration Number: NCT02248207

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy